SOCRATES 试验:负荷剂量时间与卒中复发风险的关系
结果显示 TLD<12 小时组主要终点 Kaplan-Meier 发生率为 7.5%,≥12 小时组为 6.9%;TLD<12 小时组替格瑞洛较阿司匹林主要终点风险更低(HR 0.79,95%CI 0.64-0.98,P=0.036),但治疗与 TLD 交互作用不显著。
要点
- TLD<12 小时患者主要终点发生率 7.5%,高于 TLD≥12 小时的 6.9%。
- TLD<12 小时组替格瑞洛较阿司匹林主要终点 HR 0.79(95%CI 0.64-0.98,P=0.036)。
- 治疗与 TLD 交互作用不显著,大出血与 TLD 无关。
核心结论
- TLD<12 小时患者主要终点事件率高于 TLD≥12 小时患者。
- 探索性分析中 TLD<12 小时时替格瑞洛较阿司匹林主要终点数值差异更大,但交互作用不显著。
- 大出血率在替格瑞洛与阿司匹林间相当,且与 TLD 无关。
研究设计与样本
- 主要终点为 90 天内卒中、心肌梗死或死亡复合终点,主要安全终点为大出血。
主要发现
- TLD<12 小时组 4403 例(33.5%),≥12 小时组 8723 例(66.5%)。
- 全部患者主要终点 Kaplan-Meier 发生率 TLD<12 小时为 7.5%,≥12 小时为 6.9%。
- TLD<12 小时组替格瑞洛主要终点 147/2196(6.8%),阿司匹林 184/2207(8.3%),HR 0.79(95%CI 0.64-0.98,P=0.036)。
- TLD≥12 小时组替格瑞洛主要终点 6.7%,阿司匹林 7.0%,HR 0.95(95%CI 0.81-1.12,P=0.55)。
- 治疗与 TLD 交互作用不显著,大出血率在替格瑞洛与阿司匹林间相当且与 TLD 无关。
关键数值与推荐
- TLD<12 小时组替格瑞洛 vs 阿司匹林主要终点 HR 0.79(95%CI 0.64-0.98,P=0.036)。
- TLD≥12 小时组替格瑞洛 vs 阿司匹林主要终点 HR 0.95(95%CI 0.81-1.12,P=0.55)。
临床怎么用
- 对于非心源性栓塞性非严重缺血性卒中或高危 TIA 患者,早期(<12 小时)启动替格瑞洛可能较阿司匹林进一步降低主要终点事件。
- TLD≥12 小时时替格瑞洛与阿司匹林主要终点差异不明显。
- 大出血风险与 TLD 无关,替格瑞洛与阿司匹林大出血率相当。
局限性
- 本分析为探索性分析,治疗与 TLD 交互作用不显著。
- 结果需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Recurrent ischemia risk is high in the acute period after cerebral ischemic events. Effects of antiplatelet agents may vary by time to loading dose (TLD). We explored the risk of recurrent events and safety and efficacy of ticagrelor versus aspirin in relation to TLD. Methods- We randomized 13 199 patients with noncardioembolic, nonsevere ischemic stroke, or high-risk transient ischemic attack to 90-day ticagrelor or aspirin treatment within 24 hours of symptom onset. For this analysis, 13 126 patients were categorized by TLD as <12 hours or ≥12 hours from start of index event. The primary end point was the composite of stroke, myocardial infarction, or death within 90 days. Major bleeding was the primary safety end point. Results- TLD was <12 hours in 4403 (33.5%) and ≥12 hours in 8723 (66.5%). The Kaplan-Meier% for the primary end point for all patients with TLD<12 hours was 7.5% versus 6.9% in TLD≥12 hours. Among patients with TLD<12 hours, the primary end point occurred in 147/2196 (6.8%) randomized to ticagrelor and in 184/2207 (8.3%) randomized to aspirin (hazard ratio, 0.79; 95% CI, 0.64-0.98; P=0.036). Among patients with TLD≥12 hours, the primary end point occurred in 6.7% patients randomized to ticagrelor versus 7.0% to aspirin (hazard ratio, 0.95; 95% CI, 0.81-1.12; P=0.55). There was no significant treatment-by-TLD interaction. Major bleeding rates were comparable on ticagrelor and aspirin, regardless of TLD. Conclusions- The event rate for the primary end point was higher in patients treated early (<12 hours) versus later (≥12 hours). In this exploratory analysis, a larger numerical difference in the primary end point was observed among patients on ticagrelor than on aspirin when TLD was <12 hours compared with ≥12 hours, although the interaction terms for treatment-by-TLD were not significant. For major bleeding, no relation to TLD was observed. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT01994720.
引用
- Molina CA, Johnston SC, Ladenvall P, et al. Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. Stroke. 2019. PMID: 30776996. doi:10.1161/STROKEAHA.118.022675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。